Vertex sues US over Casgevy gene editing therapy-February 2024-www.financetom.com

Vertex sues US over Casgevy gene editing therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Vertex sues US over Casgevy gene editing therapy

Jul 15, 2024 10:35 AM

July 15 (Reuters) - Vertex Phamaceuticals sued

the U.S. Department of Health and Human Services on Monday,

seeking a court declaration that a fertility support program for

patients who are prescribed its gene editing therapy Casgevy

does not violate federal anti-kickback laws.

The lawsuit was filed on the federal court in Washington,

D.C.

(Reporting by Jonathan Stempel in New York)

Previous page： FOCUS-Evercore deal accelerates talent dash as banks anticipate M&A upturn Next page： Google agrees $36 million fine for anti-competitive deals with Australia telcos

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

FOCUS-Evercore deal accelerates talent dash as banks anticipate M&A upturn

Aug 4, 2025

* Evercore ( EVR ) buys UK firm Robey Warshaw for $196 million * Deal boosts Evercore's ( EVR ) presence in EMEA, says Lindsey-Clarke * Robey Warshaw partners join Evercore ( EVR ) with payments spread over six years By Charlie Conchie, Amy-Jo Crowley and David French LONDON/NEW YORK, Aug 4 (Reuters) - Boutique deal-making adviser Evercore ( EVR...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

BioNTech's Q2 revenues double on higher COVID vaccine sales

Aug 4, 2025

FRANKFURT, Aug 4 (Reuters) - German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer ( PFE ). The company's quarterly net loss came in at 387 million euros, an improvement over a net loss of 808 million in the...

Evercore deal accelerates talent dash as banks anticipate M&A upturn

Aug 4, 2025

LONDON/NEW YORK (Reuters) -Boutique deal-making adviser Evercore accelerated its campaign to become a significant force in Europe, the world's second largest pool of M&A fees, with a purchase last week that locks in talent ahead of a possible upturn in activity. Bankers forecast a return of mega-deals following a lull in corporate deal-making linked to the uncertainty surrounding U.S. tariffs....